American Association for Cancer Research
10780432ccr151054-sup-149134_1_supp_data_3123008_ntswh6.png (1.14 MB)

Supplementary Figure S2 from Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia

Download (1.14 MB)
posted on 2023-03-31, 19:00 authored by Katja Seipel, Miguel Teixera Marques, Marie-Ange Bozzini, Christina Meinken, Beatrice U. Mueller, Thomas Pabst

Fig. S2 Sensitivity of AML cells to conventional induction treatment and small molecule p53 activators.



Purpose: In acute myeloid leukemia (AML), the transcription factors CEBPA and KLF4 as well as the universal tumor suppressor p53 are frequently deregulated. Here, we investigated the extent of dysregulation, the molecular interactions, and the mechanisms involved.Experimental Design: One hundred ten AML patient samples were analyzed for protein levels of CEBPA, KLF4, p53, and p53 modulators. Regulation of CEBPA gene expression by KLF4 and p53 or by chemical p53 activators was characterized in AML cell lines.Results: We found that CEBPA gene transcription can be directly activated by p53 and KLF4, suggesting a p53–KLF4–CEBPA axis. In AML patient cells, we observed a prominent loss of p53 function and concomitant reduction of KLF4 and CEBPA protein levels. Assessment of cellular p53 modulator proteins indicated that p53 inactivation in leukemic cells correlated with elevated levels of the nuclear export protein XPO1/CRM1 and increase of the p53 inhibitors MDM2 and CUL9/PARC in the cytoplasm. Finally, restoring p53 function following treatment with cytotoxic chemotherapy compounds and p53 restoring non-genotoxic agents induced CEBPA gene expression, myeloid differentiation, and cell-cycle arrest in AML cells.Conclusions: The p53–KLF4–CEBPA axis is deregulated in AML but can be functionally restored by conventional chemotherapy and novel p53 activating treatments. Clin Cancer Res; 22(3); 746–56. ©2015 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager